Biopharma Industry Landscape Report—uncover key trends in obesity, oncology, immunology, and AI, plus top stock picks and ...

We spoke to Örn Almarsson about the therapeutic potential of mRNA lipid nanoparticles and the techniques being used to ...

Veracyte's Q1 results beat expectations, with 18.2% revenue growth and non-GAAP EPS of $0.31 supported by a strong balance ...

In a report released today, Myles Minter from William Blair reiterated a Hold rating on Moderna (MRNA – Research Report). The company’s shares closed yesterday at $27.99. Conf ...

It’s hard to believe Moderna once had a market cap exceeding $204 billion. That was in August 2021 at or near the height of the COVID-19 pandemic. As a result of Moderna possess ...

We recently published a list of 10 Stocks That Stole the Show Today. In this article, we are going to take a look at where ...

Analysis of hospitalized patients with community-acquired pneumonia links azithromycin to lower mortality and more ...

Overall, women who received a COVID vaccine had a 19% greater risk of increase in menstrual cycle length as compared to ...

Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...

New polymer microparticles can be used to deliver vaccines at different times. The work could lead to childhood vaccines given just once, eliminating the need for booster doses.

The stock might be down substantially over the past three years, but it isn't out of the picture yet. Teladoc Health is a ...